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Abstract
Background: Recent technical developments using solid-state technology have enabled rapid image acquisition
with single photon emission computed tomography (SPECT) and have led to a renewed interest in technetium-
99m-teboroxime (Tc-99m-teboroxime) as a myocardial imaging agent. Tc-99m-teboroxime has demonstrated
high myocardial extraction, linear myocardial uptake relative to flow even at high flow rates, rapid uptake and
clearance kinetics, and differential clearance in the setting of ischemia. However, the myocardial clearance
kinetics of Tc-99m-teboroxime in a model of myocardial injury has not been previously reported. Thus, the
purposes of this study were to use a canine model of ischemia-reperfusion to (1) compare Tc-99m-teboroxime
clearance kinetics in normal and ischemic-reperfused myocardium and (2) assess the utility of Tc-99m-teboroxime
clearance kinetics in determining the severity of injury following ischemia-reperfusion.
Methods: Thirteen dogs underwent left circumflex coronary artery (LCx) occlusion for either 30 min (IR30, n=6)or
120 min (IR120, n=7), followed by reperfusion, and finally Tc-99m-teboroxime administration 120 min after reperfusion.
Microsphere blood flows were determined at baseline, during occlusion, after reperfusion, and before euthanasia.
Post-mortem, area at risk was determined using Evans blue dye, and viability was determined using triphenytetrazolium
chloride (TTC) staining. The hearts were then subdivided into 24 pieces and Tc-99m activity was measured in a
well counter.
Results: TTC-determined infarct area as a percentage of total left ventricular myocardium was 1.1%±0.3% for
the IR30 group and 7.5%±2.9% for the IR120 group (p <0.05). During coronary occlusion, both the IR30 and
IR120 groups demonstrated decreases in percent wall thickening in the ischemia-reperfusion zone (IRZ) as
compared with the normal zone (NZ). In the IR30 group, percent wall thickening in the IRZ recovered during
the reperfusion phase as compared with the NZ. In the IR120 group, percent wall thickening in the IRZ remained
depressed during the reperfusion phase and through the end of the experiment as compared with the NZ. Final
Tc-99m-teboroxime myocardial IRZ/NZ activity ratio was 0.94±0.01 for the IR30 group, compared to 0.80±0.01
for the IR120 group (p <0.05).
Conclusions: Tc-99m-teboroxime demonstrates moderate differential clearance in a model of severe injury with
120 min of ischemia-reperfusion, but only minimal differential clearance in a model of mild injury with 30 min of
ischemia-reperfusion. Thus, Tc-99m-teboroxime clearance kinetics may be helpful in differentiating normal and
minimally injured from severely injured myocardium.
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Technetium-99m-teboroxime (Tc-99m-teboroxime) is
a myocardial imaging agent that was previously available
for clinical myocardial perfusion imaging. However, image
quality was significantly compromised by the relatively
rapid myocardial clearance kinetics, and it was subse-
quently withdrawn from the market. Recently, the develop-
ment of solid-state single photon emission computed
tomography (SPECT) camera technology has provided for
faster acquisition capabilities and has led to a renewed
interest in Tc-99m-teboroxime, which is again available for
investigational use [1,2].
Tc-99m-teboroxime has several unique and favorable
properties compared with other available agents. Tc-99m-
teboroxime demonstrates high myocardial extraction, an
excellent flow to uptake relationship even at high flow rates
[3], and differential clearance both in animal models of is-
chemia [4–6] and in patients with ischemia [7–10]. How-
ever, little is known with regard to the kinetic behavior of
Tc-99m-teboroxime in models of left ventricular injury.
Tc-99m-teboroxime localizes primarily on the myocyte
membrane in cultured myocytes [11] and demonstrates
accelerated clearance following myocyte membrane in-
jury due to treatment with Triton-X100 in isolated rat
hearts [12]. Furthermore, Tc-99m-teboroxime requires
viable myocytes for retention [ 1 3 ] .T h e r e f o r e ,w eh y p o t h e -
sized that myocardial injury due to ischemia followed by re-
perfusion would lead to more rapid Tc-99m-teboroxime
myocardial clearance, which would be proportional to the
degree of myocyte injury.
Accordingly, the purposes of this study were to use a
canine model of ischemia-reperfusion to (1) compare
Tc-99m-teboroxime clearance kinetics in normal and
ischemic-reperfused injured myocardium and (2) assess
the utility of Tc-99m-teboroxime clearance kinetics in
determining the severity of injury following ischemia-
reperfusion.
Methods
All experimental animals were handled in accordance with
the guiding principles of the American Physiological Society
and by the Institutional Animal Care and Use Committee
at our institution.
Surgical model
Thirteen adult mongrel dogs (mean weight 20.2 kg,
range 15 to 24 kg) were anesthetized with sodium
pentobarbital (26 mg/kg). Supplemental anesthetic was
administered throughout the experiment as necessary.
The dogs were intubated and placed on a respirator
(Harvard Apparatus, South Natick, MA, USA) with
95% oxygen. Vinyl catheters were inserted into both
femoral arteries and the carotid artery to monitor arterial
pressure, to provide a site for microsphere reference blood
withdrawal, and to obtain specimens of blood for the deter-
mination of arterial pH, pCO2,a n dp O 2.A d j u s t m e n t sw e r e
made as necessary to maintain these parameters within a
normal physiologic range (pH =7.35 to 7.45 and pCO2=3 0
to 40 mmHg). Arterial pO2 was maintained above
100 mmHg throughout the experiment. Vinyl catheters
were also inserted into both femoral veins as sites for in-
fusion of supplemental anesthetic and fluids as required.
The heart was exposed via a left thoracotomy at the
fifth intercostal space and suspended in a pericardial
cradle. A vinyl catheter was inserted into the left atrial
appendage to monitor left atrial pressure and provide a
site for injection of radiolabeled microspheres. A
Swan-Ganz thermodilution catheter was inserted into
the left jugular vein and passed through the right side
of the heart until its tip rested in the pulmonary artery.
This catheter was subsequently used for the measurement
of cardiac output.
The left circumflex (LCx) coronary artery was then
carefully dissected free near the origin, and a 2.0 to
2.5 mm electromagnetic flow probe (SP2202 Statham
Blood Flowmeter, Gould Electronics, Dallas, TX, USA)
was placed around the artery, so that LCx blood flow
could be continuously monitored throughout the proced-
ure. A snare occluder was loosely positioned distal to the
electromagnetic flow probe. A stiff 22-gauge, 8-in. cath-
eter (Deseret Medical, Inc., Sandy, Utah) was inserted
retrograde into a small branch of the LCx for monitoring
pressure distal to the snare occluder.
Mean and phasic systemic arterial pressure, left atrial
pressure, and distal LCx pressure were continuously
monitored throughout the protocol using pressure trans-
ducers (Statham P23, Gould Electronics). Lead II of the
surface electrocardiogram was continuously monitored
throughout the protocol on an 8 channel strip chart re-
corder (Model 2800s, Gould Electronics).
Two pairs of ultrasonic dimension crystals were placed
on the endocardial and epicardial surfaces of the left
ventricle in order to record regional wall thickness and
function. One pair was placed in the zone of the myo-
cardium perfused by LCx that would eventually become
the ischemia-reperfusion zone (IRZ), and the other pair
was placed in the zone perfused by the left anterior de-
scending coronary artery (LAD) that served as the nor-
mal zone (NZ). The pinger of each pair of crystals was
located on the epicardial surface, and the receiver was
located on the endocardial surface. The crystals were
connected to a 4 channel sonomicrometer (Model 120,
Triton Technology, San Diego, CA, USA).
Preparation of Tc-99m-teboroxime
Kits for the preparation of Tc-99m-teboroxime were
supplied in a lyophilized form by Squibb Diagnostics,
Princeton, NJ, USA. A vial of teboroxime was reconstituted
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vial was then heated for 15 min at 100°C using a heating
block. After cooling to room temperature, paper chroma-
tography was performed to determine the percentage of
soluble contaminants and reduced hydrolyzed technetium.
Whatman 31 ET chromatography strips (1.3×11 cm) and
two individual mobile-phase solvent systems were used to
determine the radiochemical purity of the prepared prod-
uct. The developed chromatographs were air-dried and
counted. The results indicated that radiochemical purity
was 94.0%±0.4%. The compound was stored at room
temperature until use, which was within 6 h of preparation.
Just prior to injection, a volume of the vial with 5 mCi of
activity was withdrawn into a lead-shielded syringe.
Experimental protocol
Figure 1 illustrates the experimental protocol. Baseline
hemodynamic measurements were recorded during a
15-min period following instrumentation in all 13
dogs. Following the baseline period, microspheres were
injected to determine regional myocardial blood flows
as described below. The snare occluder on the LCx was
then tightened in order to provide complete occlusion.
A second microsphere blood flow measurement was
made following occlusion to document the absence of
coronary flow.
Six dogs undergoing mild injury received 30 min of
occlusion followed by 120 min of reperfusion (IR30).
Seven dogs undergoing severe injury received 120 min
of occlusion followed by 120 min of reperfusion (IR120).
Five mCi of Tc-99m-teboroxime were then injected into
the left femoral vein in all 13 dogs. We elected to con-
tinue reperfusion for 120 min before injecting the tracer
since myocardial injury is progressive for several hours
after the onset of reperfusion [14]. Another microsphere
blood flow determination was simultaneously performed.
A cardiac output determination using the thermodilu-
tion technique was also made at this time.
To measure blood Tc-99m activity, 1.0 ml serial arter-
ial blood samples were collected at 30-s intervals during
the first 2 min and subsequently at 2, 4, 6, 8, 10, 20, 30,
60, and 120 min after injection. At the end of 1 h, a final
myocardial blood flow determination was made by
injecting microspheres into the left atrium, and a second
cardiac output determination was made using the ther-
modilution technique. The dogs were then euthanized.
We assessed myocardial blood flow using the micro-
sphere technique as has been previously described [5].
Briefly, two to three million 11-μm radiolabeled micro-
spheres were injected into the left atrium. The micro-
spheres were labeled with either Sn-113, Ru-103, Nb-95,
or Sc-46. The order in which the microspheres were
injected was balanced across experiments. Microsphere
reference blood collection was begun 10 s prior to each
microsphere injection and continued for 2 min following
the injection.
Post-mortem ex vivo analysis
Following euthanasia, the LCx was completely re-
occluded, and the heart was infused with Evans blue dye
to delineate the area at risk. The heart was then removed
from the chest cavity and the atria and great vessels were
excised. The left ventricle was cut into four 1-cm short-
axis slices. The slices were then stained with triphenyl-
tetrazolium chloride and photographed as described
below. The LAD and LCx territories were then each
subdivided into 24 pieces. The serial blood samples and
myocardial tissue samples were counted for 3 min each
Figure 1 Experimental protocol. The IR30 group underwent 30 min of LCx occlusion followed by 120 min of reperfusion followed by
Tc-99m-teboroxime administration. The IR120 group underwent 120 min of LCx occlusion followed by 120 min of reperfusion followed by
Tc-99m-teboroxime administration. IR30, ischemia-reperfusion, 30-min occlusion group; IR120, ischemia reperfusion, 120-min occlusion group.
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ments, Gaithersburg, MD, USA) with a window setting
of 120 to 160 keV to detect Tc-99m activity. These data
were corrected for background and radioactive decay.
The following day, the microsphere reference blood
samples and the same myocardial tissue samples were
again counted for 5 min each. Appropriate window set-
tings were chosen for each microsphere isotope (Sn-113
was counted within a 350- to 435-keV window, Ru-103
within a 450- to 550-keV window, Nb-95 within a 660- to
800-keV window, and Sc-46 within a 810- to 1,200-keV
window). Proprietary software was used to correct for both
background and spillover activity from one window into
another and to calculate regional myocardial blood flow.
Regional myocardial blood flow was expressed as ml/min/g
of tissue as calculated from the microsphere count data and
tissue sample weights. Myocardial blood flow ratios were
calculated by dividing the flow in the IRZ region by the
flow in the NZ region.
Ex vivo myocardial viability assessment
After euthanasia, the left ventricle was sectioned into
four short-axis slices. Triphenyltetrazolium chloride
(TTC) staining was then performed on the four slices
to determine myocardial tissue viability. The four slices
were incubated in TTC Tris solution with pH 7.8 at
37°C for 15 min. The TTC-stained myocardial slices
were photographed and quantitatively analyzed using video
densitometry software (SigmaScan, Jandel, CA, USA) to
calculate the percentage of viable myocardium.
Data analysis and statistical methods
The first blood sample in each experiment was discarded,
as the activity of this sample was lower than that of the
30-s sample due to inadequate time for complete mixing of
Tc-99m-teboroxime in the blood pool. Background- and
decay-corrected serial blood sample data were normalized
to the percent activity at 30 s, and activity over time curves
were modeled using nonlinear regression analysis (Systat,
Inc., Evanston, IL, USA).
Well counter-determined myocardial tissue Tc-99m
activity was corrected for weight for the 24 pieces of
normal myocardium and the 24 pieces of ischemic-
reperfused myocardium. Normal zone data were combined
for the six dogs in the IR30 group as well as for the seven
dogs in the IR120 group. Ischemia-reperfusion zone data
were combined for the six dogs in the IR30 group as well
a sf o rt h es e v e nd o g si nt h eI R 1 2 0g r o u p .
All results were expressed as mean ±standard error of
the mean (SEM). Differences in continuous variables
between groups were assessed using a one-way repeated
measures analysis of variance. Post hoc comparisons
were made using Student's t test with correction for
multiple comparisons via the Bonferroni procedure
(Crunch Software Corp., Oakland, CA, USA). Within-
group comparisons were made using a paired Student's
t test. p values less than 0.05 were considered significant.
Results
Hemodynamic data
Table 1 shows complete hemodynamic data for all 13
dogs. There were no significant differences in mean ar-
terial pressure (MAP) between the IR30 and IR120
groups at baseline. During occlusion, both the IR30 and
IR120 groups had significant reductions in MAP as com-
pared to their respective baseline values. At the time of
Tc-99m-teboroxime administration and at the end of the
experiment, the IR120 group continued to have signifi-
cantly lower MAP as compared with both baseline values
and the IR30 group.
Heart rate was not significantly different between the
two experimental groups at baseline. At the time of oc-
clusion, Tc-99m-teboroxime administration, and at the
end of the experiment, the IR120 group had significantly
lower heart rate as compared with baseline values. At
the time of occlusion and at the end of the experiment,
the IR120 group had significantly lower heart rate as
compared with the IR30 group, but this did not have a
significant effect on cardiac output, which was not sig-
nificantly different between the two groups at any time
during the experiment.
Distal LCx arterial pressure was not significantly different
between the two experimental groups at baseline. At the
time of occlusion, both the IR30 and IR120 groups had
Table 1 Hemodynamic parameters
Baseline Post-occlusion Tc injection Final
MAP (mmHg)
IR30 104.3±2.4 91.0± 7.5† 102.0±1.7 103.3± 1.6
IR120 102.6±3.0 89.6± 4.1† 91.7±3.5*† 92.6±3.7*†
HR (bpm)
IR30 117.5±4.0 125.5±6.5 110.8±4.9 103.7± 3.2
IR120 125.7±9.8 103.7±3.3*† 96.6±5.0† 91.0±2.5*†
CO (ml/min)
IR30 1.8± 0.4 1.8±0.4 2.1± 0.4 2.4± 0.3
IR120 1.8± 0.1 1.7±0.1 2.5± 0.2 2.1± 0.1
DP (mmHg)
IR30 102.0±13.0 26.6± 0.7† 92.0±4.2 93.7±3.7
IR120 98.2±3.6 24.2± 0.7† 92.8±7.2 96.3±8.4
LAP (mmHg)
IR30 4.3± 0.6 8.0±1.2† 6.1± 0.6† 8.1± 0.3†
IR120 4.5± 0.3 12.7± 1.1† 6.5± 1.1† 6.2± 0.7†
*p < 0.05 compared to normal zone; †p < 0.05 compared to baseline. CO,
cardiac output; DP, distal left circumflex coronary artery pressure; IR30, 30-min
occlusion (n= 6); HR, heart rate; IR120, 120-min occlusion (n= 7); LAP, left atrial
pressure; MAP, mean arterial pressure.
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their respective baseline values. At the time of Tc-99m-
teboroxime administration and at the end of the experi-
ment, distal pressure was not significantly different from
baseline values for either group.
Left atrial pressure was not significantly different
between the two experimental groups at baseline. Begin-
ning at the time of LCx occlusion and continuing
through the end of the experiment, both the IR30 and
IR120 groups had significant rises in left atrial pressure
as compared with baseline values, but there were no sig-
nificant differences between the two groups.
Regional myocardial function
Percent left ventricular wall thickening was calculated
from sonomicrometer-determined end systolic and end
diastolic wall thicknesses at baseline, LCx occlusion, Tc-
99m-teboroxime administration, and at the end of the
experiment. These data are presented in Table 2. Both
the IR30 and IR120 groups demonstrated decreases in
percent wall thickening in the IRZ as compared with the
NZ following LCx occlusion. In the IR30 group, percent
wall thickening in the IRZ recovered as compared with
the NZ during the reperfusion phase, suggesting that
most of the IRZ suffered reversible injury in the IR30
group. In the IR120 group, percent wall thickening in
the IRZ remained decreased as compared with the NZ
during the reperfusion phase and through the end of the
experiment, suggesting that most of the IRZ suffered ir-
reversible injury in this group.
Area at risk and infarcted area
Figure 2 shows the area at risk as determined by Evans
blue staining and the percent infarcted myocardium as
determined by TTC staining for the two experimental
groups. The area at risk expressed as a percentage of
total left ventricular myocardium was 32.7% ±2.5% for
the IR30 group and 34.2% ±6.0% for the IR120 group
(p= ns). The infarcted area as a percentage of the area at
risk was 4.0% ±0.9% for the IR30 group, compared
with 23.5% ±6.9% for the IR120 group (p <0.05). The in-
farcted area as a percentage of total left ventricular
myocardium was 1.1% ± 0.3% for the IR30 group and
7.5% ±2.9% for the IR120 group (p<0.05). Figure 3
shows the TTC/Evans blue images from representative
dogs.
Myocardial blood flow ratio data
Regional myocardial blood flows were determined by the
radiolabeled microsphere technique as described above,
and flow ratios were calculated for the two experimental
groups at four time points (Figure 4). During the control
period, flow ratios (LCx/LAD) were near unity and were
not significantly different between the two groups.
Following LCx occlusion, both groups had significantly
reduced flow ratios as compared to their respective base-
line values. Following reperfusion and at the end of the
study, both groups had flow ratios that were not signifi-
cantly different as compared to their respective baseline
values.
Gamma well counted tissue ratios
Myocardial tissue in the IR120 group demonstrated
significantly lower gamma well counted Tc-99m ratio
(IRZ/NZ) at the end of 1 h (0.80 ±0.01) as compared
to the IR30 group (0.93± 0.01) (p <0.05 ) (Figure 3).
This suggests minimal differential clearance of Tc-
99m-teboroxime in the IR30 group, which sustained
mild injury, and moderate differential clearance of Tc-
99m-teboroxime in the IR120 group, which sustained
severe injury. Furthermore, the IR120 group gamma
Table 2 Wall thickening fraction
Initial Post-occlusion Tc injection Final
IR30
Normal zone 22.3±3.8 20.6± 3.6 22.7±5.1 20.3±3.2
IR zone 22.7±4.3 16.3± 1.6*† 21.6±5.3 20.8±3.9
IR120
Normal zone 18.6±1.5 19.1± 1.5 19.5±2.2 20.2±2.0
IR zone 18.2±1.3 15.5± 1.0*† 16.0±1.5 14.7±1.1*†
*p<0 . 0 5a sc o mp a re dt oI R3 0 ;†p<0.05 as compared to baseline. IR, ischemia-
reperfusion; IR30, 30-min occlusion (n=6); IR120, 120-min occlusion (n=7 ) .
Figure 2 Myocardial area at risk and infarcted area. This figure
illustrates the percentage of the total left ventricle at risk as determined
by Evans blue dye, the percentage of the area at risk that ultimately
infarcted as determined by TTC staining, and the percentage of the
total left ventricle that ultimately infarcted as determined by TTC staining.
*p<0.05 as compared to IR30. AAR, area at risk; INF, infarcted area;
IR30, ischemia-reperfusion, 30-min occlusion group; IR120,
ischemia-reperfusion, 120-min occlusion group; TLV, total left ventricle.
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lower than the IR120 group flow ratio at the time of
Tc-99m-teboroxime administration (1.05±0.06) (p<0.05).
This supports the finding of moderate differential clearance
of Tc-99m-teboroxime in the IR120 group.
Blood clearance kinetics
Figure 5 shows mean Tc-99m-teboroxime blood clear-
ance data for the two experimental groups. The activity
at each time point was normalized to peak activity. In
both groups, Tc-99m-teboroxime cleared rapidly from
the blood during the first 5 min, with slower clearance
over the remaining period of study.
Discussion
Tc-99m-teboroxime has demonstrated a number of unique
and favorable characteristics for clinical myocardial imaging
compared with other available imaging agents. Myocardial
extraction is exceptionally high [15,16] and is relatively
insensitive to metabolic impairment [11]. The agent is
an excellent flow marker, even at high flow rates
Figure 3 Examples of TTC staining/Evans blue dye images. A dog with a small infarct (A) and a dog with a large infarct (B). The open arrows
point to the infarct zones. The solid arrows point to the Evans blue-stained area at risk.
Figure 4 Myocardial blood flow and Tc-99m ratios. Myocardial
blood flow ratios (IRZ/NZ) were determined by microspheres for both
study groups at four time points. Gamma well counter-determined
myocardial tissue Tc-99m ratios (IRZ/NZ) at the end of 1 h of clearance
are also shown. *p<0.05 as compared to IR30 final Tc ratio; †p<0.05as
compared to IR120 Tc-99m flow ratio. End, 1 h after tracer administration;
IR30, ischemia-reperfusion, 30-min occlusion group; IR120, ischemia
reperfusion, 120-min occlusion group; IRZ, ischemia-reperfusion
zone; NZ, normal zone; Occl, time of LCx occlusion; Tc-99m, time of
Tc-99m-teboroxime administration.
Figure 5 Fractional Tc-99m-teboroxime blood clearance curves.
This figure displays tracer activity at each time point normalized to
peak activity. IR30, ischemia-reperfusion, 30-min occlusion group;
IR120, ischemia reperfusion, 120-min occlusion group.
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serial studies and shorter stress/rest protocols [17]. Finally,
differential clearance has been observed in animal models
of resting ischemia [4,5] and dypyridamole-mediated stress
in the setting of coronary occlusion [18], as well as in
patients with stable coronary artery disease [7,9,10].
Studies from our laboratory have suggested the poten-
tial utility of differential clearance in determining the
severity of ischemia [5].
While several studies have shown that Tc-99m-
teboroxime uptake is a flow marker independent of
myocyte viability [19–25], relatively little is known re-
garding the effects of altered myocyte viability on tracer
retention. Furthermore, the mechanism of uptake for Tc-
99m-teboroxime is unclear. Maublant et al. used cultured
myocytes to show that Tc-99m-teboroxime localizes pri-
marily to the myocyte membrane [11]. Our laboratory in
turn demonstrated accelerated clearance of the tracer fol-
lowing myocyte membrane injury due to Triton-X 100 in
an isolated perfused rat heart model [12]. Abraham and
co-workers used a porcine model of acute myocardial in-
farction with reperfusion to demonstrate that viable myo-
cytes are required for retention of Tc-99m-teboroxime
[13]. Maublant et al. demonstrated both high extraction
in cultured rat cardiac myocytes and lack of response to
the presence of metabolic inhibitors shown to accelerate
sestamibi clearance [26]. Rosenspire et al. showed rapid,
high-affinity binding to rat plasma proteins and blood
cells both in vitro and in vivo [27]. Dahlberg et al. demon-
strated that binding to blood components reduced
myocardial extraction and increased the rate of clearance
of Tc-99m-teboroxime in blood-perfused rabbit hearts
[28]. Pirro et al. also found high first-pass extraction in
rat brain and cultured cells with low transendothelial per-
meability [29]. Studies using another neutrally charged
cardiac radiotracer, 99m-Tc-NOET, have shown similar
results [30,31]. Taken together, these results indicate that
Tc-99m-teboroxime has affinity for membranes in a
variety of cell types due to its molecular characteristics
which include neutral charge, high lipophilicity, and high
hydrophobicity. Furthermore, it appears that the mechan-
ism of uptake for neutrally charged cardiac radiotracers is
not the same as that for positively charged molecules
such as thallium and sestamibi.
In the present study, we hypothesized that coronary
occlusion followed by reperfusion would lead to more
rapid myocardial clearance of Tc-99m-teboroxime
due to myocyte membrane damage resulting from
both ischemia and reperfusion injury. We used an
occlusion-reperfusion protocol with varying durations
of occlusion to produce mild (IR30) and severe (IR120)
myocardial injury, and demonstrated that Tc-99m-
teboroxime clearance kinetics can differentiate be-
tween the two.
Hemodynamics, blood flow, and contractility
The pattern of hemodynamic alterations observed was
consistent with stenosis of a major coronary artery and
included decreased systemic arterial pressure, decreased
coronary artery pressure distal to the stenosis, slightly el-
evated left atrial pressure, and decreased heart rate. The
mean arterial pressure recovered in the mild injury
group (IR30), but persisted in the severe injury group
(IR120). However, there was no difference in cardiac
output between the groups ensuring that reduced heart
rate and arterial pressure did not account for the ob-
served differences in tracer kinetics. Tc-99m-teboroxime
injection produced no observable hemodynamic changes
in these experiments.
Prior to LCx occlusion, there were no differences in
absolute microsphere-determined regional myocardial
blood flows between the two groups. As expected, abso-
lute blood flow was significantly reduced during LCx oc-
clusion and then normalized after reperfusion in both
experimental groups.
Wall thickening in the ischemia-reperfusion zone
(IRZ) decreased as expected in both groups during LCx
occlusion. Wall thickening in the IRZ normalized follow-
ing reperfusion in the IR30 group, but was persistently
decreased in the IR120 group consistent with a greater
degree of injury.
Area at risk and infarct size
The area at risk during LCx occlusion as determined by
Evans blue dye was not significantly different between
the two experimental groups. As expected, the TTC-
determined infarct size was significantly greater in the
IR120 group. Infarct size was only 1% of the total LV
area for the IR30 group.
Tc-99m-teboroxime differential clearance
Previous studies in our laboratory using a model of rest-
ing ischemia without reperfusion and without injury
demonstrated significantly reduced clearance in ischemic
zones resulting exclusively from reduced flow [32]. In a
perfused rat model, our laboratory showed markedly ac-
celerated clearance in the setting of membrane injury
due to Triton-X 100, a membrane detergent [12].
In the current study using canine models of mild
and severe injury, the final gamma well counter-
determined Tc-99m-tissue ratios (IRZ/NZ region) were
less than unity for both the IR30 and IR120 groups,
suggesting differential clearance in both groups. How-
ever, the Tc-99m-teboroxime ratio (IRZ/NZ) was sig-
nificantly lower for the IR120 group compared to the
IR30 group. This suggests more rapid IRZ tracer clear-
ance in the severe injury group (IR120) as compared to
t h em i l di n j u r yg r o u p( I R 3 0 ) .F u r t h e r m o r e ,t h ef i n a l
gamma well counter-determined Tc-99m ratio (IRZ/
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determined blood flow ratio (IRZ/NZ) at the time of
tracer administration in the severe injury group
(IR120), confirming differential clearance of the tracer
in this group.
Blood clearance kinetics
Tc-99m-teboroxime blood clearance was rapid with 90% of
the radiotracer being cleared in the first 10 min, which was
in agreement with the previous data [32]. There was no sig-
nificant difference in blood clearance between the two
groups.
Clinical implications
The current study demonstrates the potential for differenti-
a t i n gs e v e r ei n j u r yf r o mb o t hm i l di n j u r ya n dn o r m a lm y o -
cardium using differential Tc-99m-teboroxime clearance
kinetics. Fortunately, myocardial extraction from the blood
pool is rapid and permits the commencement of imaging
within minutes of tracer injection. However, as Tc-99m-
teboroxime clearance is also rapid, fast imaging protocols
are necessary. Newer solid-state SPECT imaging technol-
ogy makes such acquisitions more feasible. Quantitative
techniques may also be useful in detecting small differences
in clearance.
Conclusions
Tc-99m-teboroxime clearance kinetics differentiate severely
injured myocardium from normal and minimally injured
myocardium in a canine model of acute myocardial injury
due to coronary occlusion and reperfusion. Further clinical
studies are warranted to determine if rapid image acquisi-
tion technology will allow utilization of these kinetic prop-
erties in patient diagnosis.
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